Name: MitoQ (Mitoquinone) mesylate
Brand: Selleck Chemicals
SKU: S8978
Rating: 5 (18 reviews)

MitoQ (Mitoquinone) mesylate is a TPP-based, mitochondria-targeted antioxidant that blocks H₂O₂-induced intracellular ROS responses and protects against oxidative damage. This product is a waxy solid.

MitoQ (Mitoquinone) mesylate Chemical Structure

CAS: 845959-50-4

Selleck's MitoQ (Mitoquinone) mesylate has been cited by 18 publications

Purity & Quality Control

Batch: Purity: 99.91%

99.91

Products often used together with MitoQ (Mitoquinone) mesylate

Losartan

Mitoquinone (MitoQ10) mesylate and Losartan combined use provides additive therapeutic benefit, significantly attenuating the development of hypertension and reducing left ventricular hypertrophy.

McLachlan J, et al. J Hypertens. 2014 Mar;32(3):555-64.

Visomitin (SKQ1)

Mitoquinone (MitoQ10) mesylate and Visomitin (SKQ1) specifically target the mitochondrial matrix and are highly effective at limiting reactive oxygen species (ROS) levels.

Moustapha A, et al. Cell Death Discov. 2015 Oct 26;1:15017.

Acetylcysteine (N-acetylcysteine)

Mitoquinone (MitoQ10) mesylate is more effective at limiting reactive oxygen species (ROS) levels than N-acetylcysteine.

Moustapha A, et al. Cell Death Discov. 2015 Oct 26;1:15017.

Trolox

MitoQ10 completely inhibits mitochondrial lipid peroxidation, whereas Trolox only partially inhibits mitochondrial lipid peroxidation in pretreated hepatocytes.

Gonzalvez F, et al. PLoS One. 2010 Feb 22;5(2):e9342.

GSH (Glutathione)

Mitoquinone mesylate and Glutathione co-treatment reduces the production of ROS induced by 2-ME2, enhances the Bcl-2/Bax ratio, inhibits the activation of caspase-9/3 in SH-SY5Y cells.

Zhang Q, et al. Cancer Lett. 2011 Dec 27;313(2):201-10.

MitoQ (Mitoquinone) mesylate Related Products

Choose Selective ROS Inhibitors

Biological Activity

Description

MitoQ (Mitoquinone) mesylate is a TPP-based, mitochondria-targeted antioxidant that blocks H₂O₂-induced intracellular ROS responses and protects against oxidative damage. This product is a waxy solid.

Targets

mitochondria ^[1]

ROS ^[1]

In vitro
In vitro	Mitoquinone blocks H2O2-induced intracellular ROS responses inmurine pancreatic acinar cells. Mitoquinone does not reduce mitochondrial depolarisation induced by either cholecystokinin (CCK) or bile acid TLCS. Mitoquinone increases basal and CCK-induced cell death in a plate-reader assay.^[1]
Cell Research	Cell lines	Pancreatic Acinar Cells
	Concentrations	1 μM, 10 μM
	Incubation Time	200 s, 400 s, 600 s, 800 s, 1000 s
	Method	The cells are loaded with 40 nM TMRM for 30 minutes prior incubation with either 1 μM or 10 μM of MitoQ or dTPP. Cholecystokinin-8 (CCK-8, 10 nM) or bile acid taurolithocholic acid 3-sulphate (TLCS, 500 μM) is used to induce ΔΨm depolarisation. At the end of the perfusion, the protonophore carbonyl cyanide 3-chlorophenylhydrazone (CCCP, 10 μM) is added to induce complete depolarisation of ΔΨm. The fluorescence of TMRM is excited at 543 nm and the emission is collected at 560–650 nm.

In Vivo
In vivo	In a TLCS-induced AP model Mitoquinone treatment is not protective. In AP induced by caerulein hyperstimulation (CER-AP), Mitoquinone exerts mixed effects. Thus, partial amelioration of histopathology scores is observed but without reduction of the biochemical markers pancreatic trypsin or serumamylase. Lungmyeloperoxidase and interleukin-6 are concurrently increased by Mitoquinone in CER-AP. Mitoquinone causes biphasic effects on ROS production in isolated polymorphonuclear leukocytes, inhibiting an acute increase but elevating later levels.^[1]
Animal Research	Animal Models	C57BL/6J mice
	Dosages	10 mg/kg, 25 mg/kg
	Administration	IP

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05539625	Not yet recruiting	Ulcerative Colitis	University of Edinburgh\|The Jon Moulton Charity Trust\|MitoQ	September 2022	Phase 2
NCT04109820	Recruiting	Sickle Cell Disease	University of Pittsburgh	March 1 2020	Not Applicable
NCT04098510	Unknown status	Healthy	University of Copenhagen	September 8 2019	Not Applicable
NCT01167088	Terminated	Non-alcoholic Fatty Liver Disease	Antipodean Pharmaceuticals Inc.	November 2010	Phase 2
NCT00433108	Completed	Chronic Hepatitis C	Antipodean Pharmaceuticals Inc.	March 2007	Phase 2

References

[1] Wei Huang, et al. Mediators Inflamm. 2015;2015:901780.

Chemical Information & Solubility

Molecular Weight	678.81	Formula	C₃₈H₄₇O₇PS
CAS No.	845959-50-4	SDF	--
Smiles	CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)[O-]
Storage (From the date of receipt)	2 years -20°C liquid	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	2 years -20°C liquid		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 50 mg/mL ( (73.65 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 10 mg/mL

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):